J & J obtained daratumumab cancer drug with 1.1 billion yuan

According to the latest news in American media, Janssen biotech, a subsidiary of Johnson & Johnson pharmaceutical company, recently invested in the acquisition of daratumumab, a cancer drug made in Denmark, which is a global cancer drug Under the deal, Janssen biotech will make a down payment of up to $55 million to genmab, and J & J Development Corporation will spend $80 million to buy 5.4 million shares in genmab After the deal, Johnson & Johnson holds 10.7% of genmab If potential development, regulation and sales milestones are included, the total value of this transaction is 1.1 billion US dollars The deal, headquartered in Copenhagen, Denmark, has boosted the company's annual revenue, which is expected to rise by $10 million to between $73 million and $78 million by the end of this year Jan van de Winkel, the company's chief executive, said in an interview that the deal largely consolidated the company's economic foundation and provided some financial support for the company's future development of new antibody drugs Janssen, a subsidiary of Johnson & Johnson, said that on the one hand, it will continue to invest in supporting the first phase and second phase of experimental research and development of daratumab, and will also be responsible for all research and development and marketing activities of the drug Daratumumab belongs to the monoclonal antibody against human CD 38 molecule, which is still in the research and development stage The main indication is multiple myeloma It is reported that multiple myeloma is a very rare disease, and the current treatment is limited However, with the support of market economy experts in the pharmaceutical industry, by 2016, the total market sales of daratumab drugs may reach US $5.4 billion Once the trial is successful, daratumumab will become a strong market competitor of kyrolis, a proteasome inhibitor of ornix biopharmaceutical company, and Velcade, a Japanese pharmaceutical company At present, Onyx biopharmaceutical company is speeding up the clinical trial stage of kyrolis drug to obtain the approval for listing as soon as possible Both genmab and Janssen expressed their hope that the drug could be used to treat tumor oriented diseases, such as acute myeloid leukemia